Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis

被引：4

作者：

Batu, Ezgi Deniz ^{[1
]}

Sonmez, Hafize Emine ^{[1
]}

Gulhan, Bora ^{[2
]}

Arici, Zehra Serap ^{[1
]}

Topaloglu, Rezan ^{[2
]}

Bilginer, Yelda ^{[1
]}

机构：

[1] Hacettepe Univ, Fac Med, Dept Pediat, Div Rheumatol, Ankara, Turkey

[2] Hacettepe Univ, Fac Med, Dept Pediat, Div Nephrol, Ankara, Turkey

来源：

TURKISH JOURNAL OF PEDIATRICS | 2017年 / 59卷 / 01期

关键词：

juvenile idiopathic arthritis; methotrexate; oligoarticular; polyarticular; treatment; FAMILIAL MEDITERRANEAN FEVER; DISEASE-ACTIVITY SCORE; EFFICACY; SUBTYPE; TRIAL;

D O I：

10.24953/turkjped.2017.01.002

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Methotrexate (MTX) is the most commonly used disease modifying antirheumatic drug in juvenile idiopathic arthritis (JIA). We aimed to define predictor factors for response to MTX in Turkish children with oligo- and polyarticular JIA. We reviewed the medical files of 59 oligo- and 57 polyarticular JIA patients seen in the clinic between May 2008 and May 2013 and who received MTX for >= 6 months. MTX responders were defined as having no/low disease activity according to juvenile arthritis disease activity score 71 (JADAS71) at 6 months after MTX initiation. Median age at JIA diagnosis/MTX initiation was 70/78 months. Involvement of the small or upper extremity joints at disease diagnosis and MTX initiation was more frequent; antinuclear antibody (ANA) positivity was less frequent; acute phase reactants, JADAS71 at MTX initiation, and the frequency of polyarticular subtype were higher in MTX non-responders. In multiple logistic regression, oligoarticular JIA subtype and ANA positivity were independent predictors of MTX response.

引用

页码：6 / 12

页数：7

共 19 条

[1] Predictors of response to methotrexate in juvenile idiopathic arthritis [J].

Albarouni, Mohamed ;

Becker, Ingrid ;

Horneff, Gerd .

PEDIATRIC RHEUMATOLOGY, 2014, 12

[2] 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features [J].

Beukelman, Timothy ;

Patkar, Nivedita M. ;

Saag, Kenneth G. ;

Tolleson-Rinehart, Sue ;

Cron, Randy Q. ;

DeWitt, Esi Morgan ;

Ilowite, Norman T. ;

Kimura, Yukiko ;

Laxer, Ronald M. ;

Lovell, Daniel J. ;

Martini, Alberto ;

Rabinovich, C. Egla ;

Ruperto, Nicolino .

ARTHRITIS CARE & RESEARCH, 2011, 63 (04) :465-482

[3] Defining criteria for disease activity states in juvenile idiopathic arthritis [J].

Consolaro, Alessandro ;

Ravelli, Angelo .

RHEUMATOLOGY, 2016, 55 (04) :595-596

[4] Development and Validation of a Composite Disease Activity Score for Juvenile Idiopathic Arthritis [J].

Consolaro, Alessandro ;

Ruperto, Nicolino ;

Bazso, Anna ;

Pistorio, Angela ;

Magni-Manzoni, Silvia ;

Filocamo, Giovanni ;

Malattia, Clara ;

Viola, Stefania ;

Martini, Alberto ;

Ravelli, Angelo .

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (05) :658-666

[5] Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases [J].

Demirkaya, Erkan ;

Consolaro, Alessandro ;

Sonmez, Hafize Emine ;

Giancane, Gabriella ;

Simsek, Dogan ;

Ravelli, Angelo .

CURRENT RHEUMATOLOGY REPORTS, 2016, 18 (02) :1-10

[6]

HALLE F, 1991, CLIN EXP RHEUMATOL, V9, P297

[7] Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis [J].

Mcerlane, Flora ;

Beresford, Michael W. ;

Baildam, Eileen M. ;

Chieng, S. E. Alice ;

Davidson, Joyce E. ;

Foster, Helen E. ;

Gardner-Medwin, Janet ;

Lunt, Mark ;

Wedderburn, Lucy R. ;

Thomson, Wendy ;

Hyrich, Kimme L. .

ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (12) :1983-1988

[8]

Ozcakar ZB, 2016, QJM

[9]

Ozen S, 1998, J RHEUMATOL, V25, P2445

[10]

Ozen S, 2003, J RHEUMATOL, V30, P2014

← 1 2 →